Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors

View x

Biopharma firm Shire in talks to buy Actelion, Europe’s biggest biotech firm in a $18.32 billion takeover deal

Global speciality biopharmaceutical company Shire is in talks to takeover Europe’s biggest biotech firm Actelion in a 12 billion pound ($18.32 billion) deal. Shire’s previous informal approach some weeks back was rejected. Actelion surpassed estimates earlier this year, when it raised its full-year guidance after strong sales of its new heart and lung drug helped boost its first-quarter earnings. Sire also reported more-than expected first-quarter earnings rise in April, as a result of its first drug to treat binge eating disorder.


United Kingdom,Shire,Actelion